Published in PLoS One on August 24, 2011
Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov (2012) 4.70
The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol (2015) 1.89
Neutrophils in innate and adaptive immunity. Semin Immunopathol (2013) 1.23
Cyr61 is involved in neutrophil infiltration in joints by inducing IL-8 production by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther (2013) 1.06
Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther (2013) 1.03
Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther (2014) 0.97
Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology (2015) 0.94
Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis. Arthritis Res Ther (2012) 0.93
RORγt+IL-17+ neutrophils play a critical role in hepatic ischemia-reperfusion injury. J Mol Cell Biol (2013) 0.89
The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology (2015) 0.89
Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat Rev Rheumatol (2016) 0.86
Energy metabolism and rheumatic diseases: from cell to organism. Arthritis Res Ther (2012) 0.85
Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Res Ther (2015) 0.81
Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Res Ther (2013) 0.80
Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion. Arthritis Res Ther (2016) 0.77
The effect of interleukin 17 and Toll-like receptor 2 on CD11b expression and apoptosis of neutrophils in zymosaninduced arthritis and paw oedema. Cent Eur J Immunol (2014) 0.75
Impacts of Interleukin-17 Neutralization on the Inflammatory Response in a Healing Ligament. J Cytokine Biol (2017) 0.75
Re-Examining Neutrophil Participation in GN. J Am Soc Nephrol (2017) 0.75
[Hypoxia is a key factor in the inflammatory milieu of rheumatic diseases]. Z Rheumatol (2012) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Interleukin-17 family members and inflammation. Immunity (2004) 16.16
Interleukin-17 and type 17 helper T cells. N Engl J Med (2009) 6.83
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum (1999) 6.39
Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science (2002) 5.82
Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol (2001) 4.39
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) (2007) 3.72
Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther (2009) 3.47
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol (2010) 2.64
Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol (2011) 2.53
Induction, function and regulation of IL-17-producing T cells. Eur J Immunol (2008) 2.38
Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol (1994) 2.13
Oxidation in rheumatoid arthritis. Arthritis Res Ther (2004) 1.96
In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci U S A (2009) 1.84
Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J (2008) 1.78
IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol (2010) 1.73
Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73
Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum (2001) 1.71
The role of FcgammaR signaling in the K/B x N serum transfer model of arthritis. J Immunol (2002) 1.70
Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem (2004) 1.67
Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther (2007) 1.63
Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol (2009) 1.59
IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol (2010) 1.57
Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. Arthritis Rheum (2011) 1.50
Hypoxia prolongs neutrophil survival in vitro. FEBS Lett (1995) 1.40
A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood (2008) 1.34
Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint. PLoS One (2010) 1.31
Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol (2003) 1.31
Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther (2009) 1.28
Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol (2009) 1.28
Mast cells in inflammatory arthritis. Arthritis Res Ther (2004) 1.21
Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev (2007) 1.20
Polymorphonuclear leukocyte-mediated cell and tissue injury: oxygen metabolites and their relations to human disease. Hum Pathol (1985) 1.20
Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis (2010) 1.19
Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol (1999) 1.19
IgE enhances parasite clearance and regulates mast cell responses in mice infected with Trichinella spiralis. J Immunol (2004) 1.18
Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum (2004) 1.17
Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum (2003) 1.17
Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum (2010) 1.13
Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. J Hand Surg Am (2008) 1.12
Promotion of the local differentiation of murine Th17 cells by synovial macrophages during acute inflammatory arthritis. Arthritis Rheum (2008) 1.05
Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp Dermatol (2009) 1.02
The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int (2009) 1.01
Cytokine regulation in RA synovial tissue: role of T cell/macrophage contact-dependent interactions. Arthritis Res (2002) 1.01
Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2009) 1.01
Mast cells are early responders after hypoxia-ischemia in immature rat brain. Stroke (2009) 0.99
Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints. J Leukoc Biol (2006) 0.97
The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol (2009) 0.97
Hypoxia activates NF-kappaB-dependent gene expression through the canonical signaling pathway. Antioxid Redox Signal (2009) 0.94
An emerging role of mast cells in cerebral ischemia and hemorrhage. Ann Med (2009) 0.94
IL-17 potentiates neuronal injury induced by oxygen-glucose deprivation and affects neuronal IL-17 receptor expression. J Neuroimmunol (2009) 0.94
Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci (2008) 0.92
Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. Ann Rheum Dis (2009) 0.92
Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol (2004) 0.88
Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. Inflamm Res (2007) 0.83
Cell adhesion molecules in rheumatoid arthritis. Drugs Aging (1996) 0.78
In vitro hypoxia increases production of matrix metalloproteinases and tryptase in isolated rat lung mast cells. Physiol Res (2007) 0.78
[Mast cells and fibroblast-like synoviocytes co-culture increases interleukin-6 secretion in rheumatoid arthritis]. Zhonghua Yi Xue Za Zhi (2008) 0.77
Hypoxia enhances stimulating effect of amyloid beta peptide (25-35) for interleukin 17 and T helper lymphocyte subtype 17 upregulation in cultured peripheral blood mononuclear cells. Microbiol Immunol (2009) 0.76
Strangers at the benchside: research ethics consultation. Am J Bioeth (2008) 12.17
Ankylosing spondylitis. Lancet (2007) 6.58
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol (2015) 4.41
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum (2005) 4.12
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum (2005) 2.74
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum (2006) 2.67
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (2014) 2.52
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum (2008) 2.48
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum (2009) 2.45
Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum (2011) 2.25
An international gap in human ES cell research. Nat Biotechnol (2006) 2.17
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum (2008) 2.14
Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis (2012) 2.10
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum (2008) 2.04
Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum (2002) 1.92
Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther (2006) 1.88
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol (2005) 1.84
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med (2015) 1.83
Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum (2003) 1.79
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum (2013) 1.69
Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis (2012) 1.68
Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum (2002) 1.67
Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum (2012) 1.66
New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol (2008) 1.66
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol (2007) 1.63
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther (2011) 1.61
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther (2005) 1.61
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther (2008) 1.60
Research ethics consultation: the Stanford experience. IRB (2009) 1.58
Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol (2009) 1.58
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther (2008) 1.56
HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum (2005) 1.55
The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol (2002) 1.55
TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest (2012) 1.52
Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. Arthritis Rheum (2011) 1.50
Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol (2005) 1.43
Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. J Rheumatol (2013) 1.41
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum (2006) 1.38
Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol (2003) 1.38
Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis (2011) 1.35
Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis (2007) 1.34
Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 1.33
ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis (2010) 1.30
Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis (2012) 1.30
Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis (2013) 1.29
Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther (2009) 1.28
Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis (2010) 1.28
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum (2008) 1.27
Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum (2006) 1.27
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol (2002) 1.21
High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 1.21
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res (2002) 1.21
The stem cell research environment: a patchwork of patchworks. Stem Cell Rev (2009) 1.21
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis (2014) 1.19
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. Rheumatology (Oxford) (2011) 1.18
Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum (2003) 1.18
Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol (2010) 1.17
Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol (2006) 1.17
Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum (2006) 1.15
Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol (2004) 1.13
Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum (2010) 1.13
Macrophages in synovial inflammation. Front Immunol (2011) 1.13
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol (2007) 1.11
ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Ann Rheum Dis (2012) 1.10
Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol (2010) 1.10
Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol (2011) 1.09
Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol (2009) 1.08
Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol (2012) 1.08
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum (2006) 1.07
Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther (2010) 1.06
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis (2013) 1.05
Outcome measures in psoriatic arthritis. J Rheumatol (2007) 1.05